With Covid-19 affecting more than 72 countries around the world and causing thousands of deaths, everyone wants to know when COVID-19 antigens and vaccines will be created to help people who are infected and those who are not yet affected. Although the scientific community and vaccine producers are working day and night on the war scale to produce effective vaccines to treat this virus, they accept that effective and completely safe vaccines take about a year to develop. The WHO having declared a pandemic and closings taking place in every city and country in the world, this wait can seem like an eternity. Most vaccines for adequate and large-scale development take 5 to 15 years to reach the market. Therefore, producing an effective vaccine to treat Covid-19 in a short time can be a record.
Factors for consuming enough time to develop vaccines.
Several reasons are cited for requiring sufficient time to develop effective drugs, such as recombinant coronavirus antigens, to treat Covid-19. It is necessary to organize a candidate vaccine ready to be tested. This stage of vaccine development is called discovery and takes many years of office biology. Viruses must be isolated and cultured in the laboratory. However, with genetic sequencing and the introduction of new technological advances and protein visualization microscopes, it is possible to avoid this step. The determination of the vaccine candidate is now possible in a few weeks.
However, all the advances made may not be able to accelerate the time devoted to meticulous monitoring of the effectiveness of candidate vaccines in humans. A prerequisite in the form of clinical trials to place the vaccine on the market can be seen as a real bottleneck. They are carried out in 3 stages.
1) The first step involves healthy volunteers in a few dozen to analyze whether the vaccine is completely safe. It will take about three months.
2) If no undesirable effects are observed in healthy volunteers, the investigation proceeds to the second phase. At this point, hundreds of people are receiving a nCoV 2019 recombinant vaccine, ideally in the area affected by the Covid-19 epidemic. This allows scientists to collect data on its effectiveness and how the production of antibodies is stimulated and eliminates the disease in the test subjects. This process takes between 6 and 8 months.
3) In case the situation is under control, the process enters the third phase, where thousands of people are recruited in the area of the epidemic. Here, the experiment is repeated. It takes another 6 to 8 months, as there is no problem with patient recruitment or the availability of vaccine supply. The Food and Drug Administration must then review the data before making the decision to proceed with the approval of the coronavirus protein vaccine, which could take anywhere from a few months to about a year.
The whole process, if calculated correctly, which begins development of the vaccine in January, the version approved for public use will be available on the market no earlier than summer 2021. This is possible if research is carried out. unfolds perfectly as expected without any setbacks. . In fact, it is a Herculean task that constrains the entire chronology, from the concept to the creation of a product that can be distributed transparently in a few years. To find out more, find out at https://www.genemedi.net/
It's just a handful of manufacturers who have vaccine candidates to quickly take the next step, which is the human test. Many companies around the world are racing to create the perfect vaccine to treat Covid-19 at an affordable price. Even if they manage to create a product, they still have to do the manufacturing and distribution. The question that the general public will ask these companies is whether the producer will have the capacity and resources to increase production to meet the growing demands of the large population around the world. Otherwise, health officials are likely to have difficulty rationing the vaccine due to a limited supply.
How to speed it up?
Delays are generally quite difficult to compress. Regulators and drug manufacturers are trying to avoid presenting inferior products which, instead of helping to treat patients, could make the situation worse. The truth is that making vaccines is high risk and expensive, and therefore many small businesses avoid it. Fortunately, there are few large companies that serve the global market and have the capacity to fight the global pandemic. Its scientists are doing their best to develop affordable vaccines that are effective enough to cure infected patients. The respective governments are also doing their part to encourage vaccine manufacturers to accept the challenge of the pandemic Covid-19 virus by providing the financial incentives and stimuli necessary to accelerate the pace of vaccine development.